Scars After Central Venous Catheters

Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01113125

Enrollment

Registered

2010-04-29

Start date

2010-03-31

Completion date

2016-07-31

Last updated

2014-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Scars, Keloids

Keywords

hypertrophic scar, keloid, central venous catheter, children, cancer

Brief summary

Most children with cancer need a central venous catheter. These catheters are typically placed on the anterior thorax, where the risk of hypertrophic scarring and keloid development is greatly enhanced. A significant part of the children who have survived childhood cancer are troubled by their scars. Topical glucocorticoid treatment is known to induce a reduction of the collagen in the connective tissue. The investigators hypothesize that treatment with topical glucocorticoids for one week before and three weeks after removal of a central venous catheter, will reduce the formation of hypertrophic scarring and keloid development in children.

Interventions

DRUGBetamethason-17-valerate and fusidic acid

0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks

DRUGFusidic Acid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

No minimum to 21 Years

Healthy volunteers

Inclusion criteria

* All children and adolescents who have a central venous catheter removed at the Childrens Department of Oncology at Aarhus University Hospital Skejby in the period from March 2010 to July 2011

Exclusion criteria

* Known allergy towards plaster or fusidic acid

Design outcomes

Primary

Measure	Time frame
scars measured by the Vancouver Scar Scale twelve months after central venous catheter removal	Twelve months

Secondary

Measure	Time frame
Judgement of the scar by Patient and observer scar scale after six months	six months
Judgement of the scar by Patient and observer scar scale after twelve months	twelve months
scars measured by the Vancouver Scar Scale six months after central venous catheter removal	six months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026